Search
European Affairs Committee
Committee members
Elizabeth Macintyre, France (Chair)
Antonio Almeida, Portugal
Natacha Bolaños, Spain (Patient advocate)
Lorenzo Brunetti, Italy
Raffaella Colombatti, Italy
Julio Delgado, Spain
Isabelle Durand-Zaleski, France (Advisory member)
Tarec El-Galaly, Denmark
Martin Kaiser, Germany
Frank Leebeek, The Netherlands (Advisory member)
Kate Morgan, United Kingdom (Patient advocate)
Marek Mraz, Czech Republic
Kostas Stamatopoulos, Greece
AimThe…
Clinical Case Unit
Current committee members
Marielle Wondergem, The Netherlands (Editor-in-Chief)
Barbara Bain, United Kingdom (Editor)
John Burthem, United Kingdom (Editor)
Mary Frances McMullin, United Kingdom (Editor)
Christopher McNamara, United Kingdom (Editor)
AimThe Clinical Case Unit guards the quality and consistency of all cases presented at EHA Tutorials and…
Publications
Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY
Thomas Chatzikonstantinou; Lydia Scarfò; Georgios Karakatsoulis; Eva Minga; Dimitra Chamou; Gloria Iacoboni; Jana Kotaskova; Christos Demosthenous; Lukas Smolej;…
Chairs and Members
ChairGiancarlo Castaman, University of Florence - Careggi University Hospital, Florence (Italy)
Co-chairAnna Falanga, University of Milan Bicocca and Hospital Papa Giovanni XXIII, Bergamo (Italy)
SWG Steering Committee
Ajay K Kakkar, Thrombosis Research Institute, London (United Kingdom)
Augusto Federici, University of Milan, University Hospital Luigi…
How to apply for CBTH
TimelinesApplication CBTH 2025
Deadline: September 24, 2024 (15:00 CEST)
Notification
November 2024
How to apply?Download the signature letter template. Fill in the template and get it duly signed for upload into the online application platform.
Treatment of acute lymphoblastic leukemia by activation of patient's immune cells by a bispecific antibody.
Abstract S722
Acute lymphoblastic leukemia (ALL) is a rare type of blood cancer which is mainly treated by intensive chemotherapy.